TBPH - テラバンス・バイオファ―マ (Theravance Biopharma Inc.) テラバンス・バイオファ―マ

 TBPHのチャート


 TBPHの企業情報

symbol TBPH
会社名 Theravance Biopharma Inc. (テラバンス・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 セラバンス・バイオファーマ(Theravance Biopharma Inc.)はバイオ医薬品会社である。同社は重病患者のための医薬品の製造に従事する。同社はヒト治療法の発見(研究)・開発・商業化の分野で事業を行う。同社の内部で発見された製品候補のパイプラインには、主に急性期ケア環境で重篤な状態で治療されている患者の満たされていないニーズに対応するための医薬品が含まれる。製品VIBATIV(テラバンシン)は、特定の治療が困難な感染症向けの一日一回の二重機構の抗生物質であり、米国および欧州で承認される。レベフェナシン(TD-4208)は、長期作用性ムスカリンアンタゴニスト(LAMA)であり、慢性閉塞性肺疾患のための噴霧治療として開発される。ネプリライシン(NEP)阻害剤プログラムは、一連の心血管疾患および腎疾患の治療のための選択的NEP阻害剤を開発するように設計されている。   テラバンス・バイオファ―マは細菌感染症と呼吸器系疾患に焦点を置く米国のバイオ医薬品会社。重度の感染症の治療用に1日1回投与の抗菌薬注射剤「VIBATIVTM(一般名:テラバンシン)」を商品化。また、製品パイプラインに慢性閉塞性肺疾患の治療用のTD-4208とオピオイド誘発性便秘薬Axelopran(TD-1211)を含む。   Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Its research is focused in the areas of inflammation and immunology.
本社所在地 P.O. Box 309 Ugland House South Church Street George Town Grand Cayman KY1-1104 CYM
代表者氏名 Rick E. Winningham リックE.ウィニングハム
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 345-650808-6000
設立年月日 41456
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 340人
url www.theravance.com
nasdaq_url https://www.nasdaq.com/symbol/tbph
adr_tso
EBITDA EBITDA(百万ドル) -246.19500
終値(lastsale) 32.555
時価総額(marketcap) 1793914854.485
時価総額 時価総額(百万ドル) 1644.307
売上高 売上高(百万ドル) 40.58500
企業価値(EV) 企業価値(EV)(百万ドル) 1515.686
当期純利益 当期純利益(百万ドル) -259.70400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Theravance Biopharma Inc revenues increased from $6.6M to $31.8M. Net loss decreased 20% to $105.9M. Revenues reflect Revenue from collaborative arrangements increase from $72K to $22.8M Product sales increase of 39% to $9M. Lower net loss reflects Research and development - bal decrease of 31% to $50.5M (expense) Interest and other income increase of 41% to $3.5M (income).

 TBPHのテクニカル分析


 TBPHのニュース

   Acute Lung Injury Market: Industry Analysis, Drugs, Key Companies by DelveInsight | Altor BioScience, Apeiron Biologics, Theravance Biopharma, Viela Bio, ReAlta Life Sciences, Cantex Pharmaceuticals  2021/05/18 01:22:01 AB Newswire
   Theravance Biopharma (NASDAQ:TBPH) Price Target Lowered to $39.00 at SVB Leerink  2021/05/12 11:42:46 Dakota Financial News
Theravance Biopharma (NASDAQ:TBPH) had its price objective lowered by SVB Leerink from $40.00 to $39.00 in a research report sent to investors on Tuesday morning, Benzinga reports. SVB Leerink currently has an outperform rating on the biopharmaceutical companys stock. SVB Leerink also issued estimates for Theravance Biopharmas Q2 2021 earnings at ($0.78) EPS, Q3 2021 []
   Head-To-Head Contrast: Spotlight Innovation (OTCMKTS:STLT) vs. Theravance Biopharma (NASDAQ:TBPH)  2021/05/12 01:06:44 Dakota Financial News
Spotlight Innovation (OTCMKTS:STLT) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability. Insider and Institutional Ownership 80.4% of Theravance Biopharma shares are owned by institutional investors. 5.9% []
   Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of Buy from Analysts  2021/05/11 20:20:41 Transcript Daily
Theravance Biopharma, Inc. (NASDAQ:TBPH) has earned a consensus recommendation of Buy from the nine analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage []
   Theravance Biopharma (NASDAQ:TBPH) Price Target Lowered to $32.00 at Needham & Company LLC  2021/05/11 14:06:41 Dakota Financial News
Theravance Biopharma (NASDAQ:TBPH) had its price objective reduced by investment analysts at Needham & Company LLC from $40.00 to $32.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical companys stock. Needham & Company LLCs price target would indicate a potential upside of 66.75% []
   20 Short Ideas With Super-Weak Momentum  2021/05/31 14:39:53 Seeking Alpha
   Theravance Biopharma to Participate in an Upcoming Investor Conference  2021/03/02 11:00:00 PR Newswire
DUBLIN, March 2, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in a pre-recorded Fireside Chat at the H.C….
   Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update  2021/02/23 21:05:00 PR Newswire
DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2020. "2020 was a critical year of growth for YUPELRI, with our commercial…
   The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings  2021/02/20 14:36:28 Benzinga
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week. Bluebird bio Inc (NASDAQ: BLUE ) was among the worst performers of the week after the company temporarily stalled its gene therapy studies in sickle cell disease. A day after bluebird bio shared the negative tidings, Novartis AG (NYSE: NVS ) announced an agreement with the Bill & Melinda Gates Foundation for funding the development of a single-administration, in-vivo gene therapy to cure sickle cell disease. The week also witnessed the forging of a few alliances and partnerships, a slew of follow-on offerings and some vaccine updates. Here are the key catalytic events for the coming week: Conferences: Annual SVB Leerink Global Healthcare Conference (virtual event): Feb. 22-26 Citi Healthcare Services Virtual Conference (virtual event): Feb. 24-25 Americas Committee for Treatment and Research in Multiple Sclerosis, or ACTRIMS, Forum (virtual event): Feb. 25-27 PDUFA Dates The Food and Drug Administration is scheduled to rule on Sarepta Therapeutics Inc's (NASDAQ: SRPT ) new drug application for casimersen, a treatment for patients with Duchenne muscular dystrophy who have certain genetic mutations.
   Theravance Biopharma to Participate in Upcoming Investor Conferences  2021/02/10 11:00:00 PR Newswire UK
DUBLIN, Feb. 10, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in investor events as follows: Management will be…
   Theravance Biopharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 23, 2021  2021/02/09 11:00:00 PR Newswire
DUBLIN, Feb. 9, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its fourth quarter and full year 2020 financial results…

 関連キーワード  (医薬品 米国株 テラバンス・バイオファ―マ TBPH Theravance Biopharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)